India, June 26 -- Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company focused on rare diseases, announced it will host an investor event to provide updates on its Nomlabofusp program for Friedreich's ataxia. The webcast is scheduled for Monday, June 29, 2026, at 7:45 a.m. ET.
Friedreich's ataxia is a progressive, inherited neurodegenerative disorder that affects coordination, mobility, and overall quality of life. Larimar's lead compound, Nomlabofusp, is being developed as a potential treatment for both adults and children with the condition.
During the event, the company will share a regulatory update and data from the ongoing Phase 2 long-term open-label study of Nomlabofusp. Larimar also plans to leverage its intr...